Core Viewpoint - The quality crisis during the "618 shopping festival" has significantly impacted the performance of Juzhi Biotechnology (02367.HK), although the company still reported revenue and net profit growth in the first half of the year, the growth rate has notably slowed compared to the previous year [1][2]. Financial Performance - In the first half of the year, Juzhi Biotechnology achieved revenue of 3.113 billion yuan, representing a year-on-year growth of 22.5%, while the net profit attributable to shareholders was 1.182 billion yuan, up 20.2% year-on-year [1]. - In the same period last year, the company's revenue and net profit growth rates were 58.2% and 47.4%, respectively, indicating a significant slowdown in performance this year [1]. - The company's largest brand, Kefu Mei, generated revenue of 2.542 billion yuan with a growth rate of 22.7%, while the second-largest brand, Keli Jin, achieved revenue of 500 million yuan, growing by 26.9% [1]. Market Outlook - The company previously set a 2025 revenue growth target of 25%-28%, and some analysts believe that the first half performance is still acceptable compared to this target [1]. - Following the quality crisis, the management described the operating conditions as "turbulent" but emphasized that the short-term impact will eventually pass [2]. - Third-party data indicates a recovery in online sales for the company's brands in July, with Kefu Mei's GMV growing by 32% year-on-year from January to July and by 62% in July alone, while Keli Jin's GMV decreased by 7% from January to July but increased by 35% in July [2]. Industry Context - The collagen industry is showing signs of cooling after several years of rapid growth, with competitors like Jinbo Biotechnology also reporting a significant slowdown in Q2 performance, raising concerns about the industry [2]. - More companies are entering the market, with brands like Shuerjia and Furuida launching related technologies or products in the first half of the year [2].
质量“罗生门”冲击业绩，巨子生物H1营收增速降至23%｜财报解读